Advanced Medical Solutions Group (LSE:AMS), the Cheshire-based maker of surgical and wound care products, has become the subject of a steady stream of Takeover Code filings in November 2026. Since early in the month, these have included a large number of Form 8.3 and Form 8.5 dealing disclosures, together with Rule 2.9 announcements dated 4, 6, 9 and 13 November confirming its share capital. Such filings are typically required once a company enters an offer period.

What the company does

AMS develops and manufactures products for the surgical, wound closure and advanced wound care markets. Its brands include tissue adhesives, sutures, haemostats and dressings, sold to hospitals and healthcare providers around the world, both under its own names and through partners. The group has expanded through a series of acquisitions in recent years.

Latest developments

The most recent Rule 2.9 announcement, dated 13 November 2026, said the company had 221,189,604 ordinary shares of 5p in issue, with none held in treasury. Earlier Rule 2.9 notices gave slightly lower totals, reflecting small share issues. These announcements also remind holders of 1% or more of the relevant securities of their obligation to publish Opening Position and Dealing Disclosures under Rule 8 of the Takeover Code.

Many dealing disclosures have followed. One Form 8.3 published on 13 November showed Societe Generale holding an interest of 3.84%, and recorded a contract for difference dealing at £2.83 per share on 12 November. On 4 November AMS also published a holding notification from Octopus Investments, which said its stake had fallen to 5.61% from 6.92% on 2 November.

The filings do not confirm whether any approach has been made, by whom, or whether an offer will follow. Readers should consult the company's own announcements for the full position.

Financial picture

No results or trading update appeared among the company's most recent announcements, which have been dominated by takeover-related filings. AMS has historically paid dividends.

Sector and index context

AMS is one of the larger healthcare companies on AIM and a notable constituent of the FTSE AIM All Share Index. UK small and mid-sized companies have attracted interest from trade and Private Equity buyers in recent years, as valuations have lagged those in other markets. Medical technology businesses with established products and recurring hospital Demand are often seen as attractive targets.

Key risks

Where an Offer Period exists, share prices can be heavily influenced by speculation about a bid and its price, and can fall sharply if talks end without an offer. More generally, AMS faces risks from healthcare procurement pressure, regulatory approvals in key markets such as the US and Europe, competition from larger medical device groups and the integration of acquired businesses.

What to watch next

The main point to watch is any formal statement from AMS or a potential bidder, such as an announcement under Rule 2.4 or a firm offer under Rule 2.7 of the Takeover Code, and any deadlines that may apply. Further Form 8 disclosures will show how institutional holders are positioning, while any trading update would give a fresh view of the underlying business.